文献速递心脑血管急症

替罗非班联合溶栓与单纯溶栓治疗急性缺血性卒中的疗效与安全性:一项Meta分析

The efficacy and safety of tirofiban plus thrombolysis and thrombolysis alone for acute ischemic stroke: A meta-analysis.
PubMed 文献 · Am J Emerg Med · 2025-10-30
一句话结论Meta分析显示替罗非班联合溶栓较单纯溶栓改善急性缺血性卒中90天功能结局,未增加症状性颅内出血、无症状性颅内出血、其他部位出血或死亡。

该Meta分析纳入6项随机对照试验共1524例急性缺血性卒中患者,比较替罗非班桥接溶栓与单纯溶栓的疗效与安全性。主要结果显示,替罗非班联合溶栓组90天改良Rankin量表(MRS)0-2分(良好功能结局)显著优于单纯溶栓组(Log RR 0.17,p<0.001)。症状性颅内出血(sICH)、无症状性颅内出血(aICH)、其他部位出血及死亡率两组间无显著差异(分别Log RR 0.60,p=0.21;Log RR -0.04,p=0.87;Log RR 0.09,p=0.74;Log RR 0.04,p=0.90)。作者认为替罗非班联合溶栓与更好的功能结局相关,但需进一步研究其安全性及目标人群的应用。

要点

  • 替罗非班联合溶栓组90天MRS 0-2分(良好功能结局)显著优于单纯溶栓组(Log RR 0.17,p<0.001)。
  • 症状性颅内出血两组无显著差异(Log RR 0.60,p=0.21)。
  • 无症状性颅内出血、其他部位出血及死亡率两组均无显著差异(分别Log RR -0.04,p=0.87;Log RR 0.09,p=0.74;Log RR 0.04,p=0.90)。
  • 作者建议进一步研究应关注替罗非班的安全性及目标患者人群的应用。

适用人群与场景

  • 急性缺血性卒中患者,纳入比较替罗非班桥接溶栓与单纯溶栓的随机对照试验。

研究设计与关键结果

  • 研究类型:Meta分析,纳入6项随机对照试验(RCT),共1524例参与者。
  • 主要终点:替罗非班联合溶栓组90天改良Rankin量表(MRS)0-2分(良好功能结局)显著优于单纯溶栓组(Log RR 0.17,p<0.001)。
  • 安全性终点:症状性颅内出血(sICH)两组无显著差异(Log RR 0.60,p=0.21);无症状性颅内出血(aICH)无显著差异(Log RR -0.04,p=0.87);其他部位出血无显著差异(Log RR 0.09,p=0.74);死亡率无显著差异(Log RR 0.04,p=0.90)。

证据类型、等级与局限

  • 证据类型:Meta分析(纳入6项随机对照试验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于急性缺血性卒中患者,替罗非班联合溶栓与更好的90天功能结局相关,且未增加症状性颅内出血、无症状性颅内出血、其他部位出血或死亡风险。
  • 作者建议进一步研究应关注替罗非班的安全性及目标患者人群的应用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Acute ischemic stroke (AIS) is a cerebrovascular disease associated with high disability and mortality. Tirofiban, a platelet glycoprotein IIb/IIIa receptor antagonist, is used in conjunction with thrombolysis for bridging therapy, but its effectiveness and safety compared with thrombolysis alone in patients with stroke are not well-established.

MATERIAL AND METHODS: PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched for randomized controlled trials (RCTs) from inception to June 17, 2025. Trials reporting the effectiveness and safety of tirofiban bridging after thrombolysis compared with thrombolysis only in patients with acute ischemic stroke were included.

RESULTS: Six RCTs with 1524 participants were included. Tirofiban plus thrombolysis significantly favored improved neurologic function based on both modified Rankin Scale (MRS) 0-2 (Log risk ratio [RR] 0.17; p < 0.001) at day 90. There was no significant difference in symptomatic intracranial hemorrhage (sICH), asymptomatic intracranial hemorrhage(aICH), bleeding from other sites and mortality between the 2 groups (LogRR 0.60; p = 0.21; LogRR -0.04; p = 0.87; LogRR 0.09; p = 0.74; LogRR 0.04; p = 0.90).

CONCLUSIONS: Tirofiban plus thrombolysis was associated with better functional outcomes, but not sICH, aICH, bleeding from other sites, or mortality among patients with AIS compared with thrombolysis only. Further studies should focus on its safety profile and application to target patients.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Bai P, Yao Y, Zhen J, et al. The efficacy and safety of tirofiban plus thrombolysis and thrombolysis alone for acute ischemic stroke: A meta-analysis. Am J Emerg Med. 2025. PMID: 41197424. doi:10.1016/j.ajem.2025.10.048

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。